Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Extended validation of the RR6 prognostic model at 6 and 12 months in primary and secondary myelofibrosis patients treated with ruxolitinib

Erika Morsia, Dorela Lame, Michelangelo Pianelli, Giorgio Gramazio, Sonia More', Shahram Kordasti, Serena Rupoli, Antonella Poloni

Blood (2025) 146 (Supplement 1): 7350.

https://doi.org/10.1182/blood-2025-7350

Published: 2025

Journal Articles

Personalized prognostic model for multiple myeloma patients using continuous variables

Sonia More', Alfonso Piciocchi, Samuele Confalone, Sara Bringhen, Mattia D'Agostino, Francesca Gay, Michele Cavo, Elena Zamagni, Pieter Sonneveld, Niels W.C.J. Van De Donk, Laura Corvatta, Maria Teresa Petrucci, Francesca Fazio, Mario Boccadoro, Massimo Offidani

Blood (2025) 146 (Supplement 1): 7563.

https://doi.org/10.1182/blood-2025-7563

Published: 2025

Journal Articles

The treatment of transplant eligible primary plasmacell leukemia patients: An italian real-life Study

Blood (2025) 146 (Supplement 1): 3977.

https://doi.org/10.1182/blood-2025-3977

Published: 2025

Journal Articles

Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025: A real life multicentre analysis in Italy

Blood (2025) 146 (Supplement 1): 4002.

https://doi.org/10.1182/blood-2025-4002

Published: 2025

Journal Articles

Cytokine signatures predict response, progression, and immune-related toxicity in Sézary syndrome patients treated with mogamulizumab

Erika Morsia, Laura Gurguglione, Riccardo Ceccarelli, Sonia More', Shahram Kordasti, Antonella Poloni, Serena Rupoli

Blood (2025) 146 (Supplement 1): 5430.

https://doi.org/10.1182/blood-2025-5430

Published: 2025

Journal Articles

Main biologic and clinic features at presentation and treatment results in very elderly patients (> 75 Years) with Multiple myeloma: A multicentric experience

Gabriella Tomei, Sonia Morè, Francesca Di Landro, Velia Bongarzoni, Francesca Fazio, Carmine Liberatore, Giusy Antolino, Silvia Gentili, Angela Rago, Laura De Padua, Paola Arcuri, Barbara Anaclerico, Maria Teresa Petrucci, Elena Rossi, Massimo Offidani, Alessandro Andriani, Roberto Latagliata

Blood (2025) 146 (Supplement 1): 5777.

https://doi.org/10.1182/blood-2025-5777

Published: 2025

Journal Articles

The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study

Blood (2025) 146 (Supplement 1): 6363.

https://doi.org/10.1182/blood-2025-6363

Published: 2025

Journal Articles

Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis

Sonia More', Valentina Maria Manieri, Laura Corvatta, Erika Morsia, Shahram Kordasti, Attilio Olivieri, Antonella Poloni, Massimo Offidani

Blood (2024) 144 (Supplement 1): 3323.

https://doi.org/10.1182/blood-2024-205518

Published: 2024

Journal Articles

The Role of TET2 Mutation in Patients with Myeloproliferative Neoplasms and Thrombosis in Unusual Sites (Splanchnic Thrombosis and Cerebral Thrombosis)

Erika Morsia, Paola Ranalli, Stefano Baldoni, Dorela Lame, Sonia More', Gaetano La Barba, Fabiola Saladino, Antonella Poloni, Attilio Olivieri, Serena Rupoli, Mauro Di Ianni, Shahram Kordasti

Blood (2024) 144 (Supplement 1): 6645.

https://doi.org/10.1182/blood-2024-207881

Published: 2024

Journal Articles

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Blood (2024) 143 (7): 592–596.

https://doi.org/10.1182/blood.2023022080

Published: 2024

Includes: Supplemental data

Journal Articles

Updated Analysis of a Prospective, Multicenter, Observational Study on the Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma

Blood (2023) 142 (Supplement 1): 4713.

https://doi.org/10.1182/blood-2023-189193

Published: 2023

Journal Articles

Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study

Blood (2022) 140 (Supplement 1): 10027–10028.

https://doi.org/10.1182/blood-2022-168619

Published: 2022

Journal Articles

Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis

Erika Morsia, Elena Torre, Francesca Marrara, Sonia Morè, Mauro Petrini, Valentina Maria Manieri, Laura Gurgoglione, Guido Gini, Massimo Offidani, Attilio Olivieri, Serena Rupoli

Blood (2022) 140 (Supplement 1): 11375.

https://doi.org/10.1182/blood-2022-163790

Published: 2022

Journal Articles

Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

Blood (2022) 140 (Supplement 1): 7147–7149.

https://doi.org/10.1182/blood-2022-165338

Published: 2022

Journal Articles

Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

Blood (2021) 138 (Supplement 1): 4871.

https://doi.org/10.1182/blood-2021-152907

Published: 2021

Journal Articles

Dynamic Features Occurring during Multiple Myeloma Course Can Modify the Outcome Predicted at Diagnosis By R-ISS Stage

Massimo Offidani, Laura Corvatta, Sonia Morè, Valerio Mori, Silvia Gentili, Kimberly Blaine Garvey, Alessandra Bossi, Laura Maracci, Pietro Leoni

Blood (2016) 128 (22): 3263.

https://doi.org/10.1182/blood.V128.22.3263.3263

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Extended validation of the RR6 prognostic model at 6 and 12 months in primary and secondary myelofibrosis patients treated with ruxolitinib

Personalized prognostic model for multiple myeloma patients using continuous variables

The treatment of transplant eligible primary plasmacell leukemia patients: An italian real-life Study

Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025: A real life multicentre analysis in Italy

Cytokine signatures predict response, progression, and immune-related toxicity in Sézary syndrome patients treated with mogamulizumab

Main biologic and clinic features at presentation and treatment results in very elderly patients (> 75 Years) with Multiple myeloma: A multicentric experience

The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study

Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis

The Role of TET2 Mutation in Patients with Myeloproliferative Neoplasms and Thrombosis in Unusual Sites (Splanchnic Thrombosis and Cerebral Thrombosis)

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Updated Analysis of a Prospective, Multicenter, Observational Study on the Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma

Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study

Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis

Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

Dynamic Features Occurring during Multiple Myeloma Course Can Modify the Outcome Predicted at Diagnosis By R-ISS Stage

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only